Seeing is believing: ultra-high field magnetic resonance imaging in vascular and neurodegeneration research


Published: 23 November 2022
Abstract Views: 173
PDF: 104
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Ultra-high field (UHF) magnetic resonance (MR) refers to a main operating field strength of 7 teslas (T) or higher. UHF MR offers unique opportunities for revealing new insights into the microstructures and functions of the brain that are not available on conventional field strength MR. Recently, the U.S. Food and Drug Administration (FDA) has cleared the 7 T magnetic resonance imaging (MRI) device for clinical use, which has doubled the 7 T systems installed in the US. Central to this powerful evolution is the concomitant increase of signal-to-noise ratio (SNR) and susceptibility contrast at UHF MRI. Compared to 3 T, 7 T offers a 2 to 3-fold increase in image SNR, which will allow us to image high resolution with voxel volume of less than 0.1 mm3, while the largely increased susceptibility or T2* contrast at ultra-high field MRI will be the key benefit for brain imaging. Sequences sensitive to magnetic susceptibility include susceptibility-weighted imaging (SWI) and quantitative susceptibility mapping (QSM). Thanks to the susceptibility-induced blooming effect, small veins at a micro level (e.g. <50 µm) can be seen on 220 x 220 µm matrix size SWI.1 With the strengths being provided on UHF MR, several key clinical benefits are discussed. The perivenous lesion development or central vein sign in multiple sclerosis (MS) has been revealed in vivo for the first time,2 which has proved useful for a differential diagnosis of MS.3 Seven teslas MRI showed improved detection of cortical MS lesions that are consistent with histopathological patterns of cortical demyelinating lesions regarding their cortical layer involvement that are not seen on 3 T MRI.4 The visibility of small venous architecture, including small cortical and medullary veins, has an important implication for tissue oxygen utilization and neuronal degeneration.5 By introducing an ultrasmall-superparamagnetic-iron-oxide (USPIO) contrast agent (e.g., ferumoxytol), the small arterioles can also be seen on 7 T SWI, which allows the detection of small arterial tortuosity in the elderly, likely the major cause of small vessel disease. Seven teslas markedly increased the sensitivity in detecting iron deposition and microbleeds associated with brain structures and lesions, and this provides critical insights on brain pathology, in particular in age-related neurodegenerative diseases. Seven teslas MRI improves the characterization of age-related choroid plexus degeneration, including both volume and signal changes, which may have an impact on waste clearance and cerebrospinal fluid (CSF) production. Figure 1 demonstrates a few representative examples of the potential of 7 T. In summary, seeing the unseen on 7 T provides opportunities not only for an early diagnosis, but also for clinical research of disease mechanisms and treatment strategy development.


[1] Buch S, Wang Y, Park MG, et al. Subvoxel vascular imaging of the midbrain using USPIO-Enhanced MRI. Neuroimage 2020;220:117106.
[2] Ge Y, Zohrabian VM, Grossman RI. Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. Arch Neurol 2008;65:812-6.
[3] Kister I, Ge Y, Herbert J, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013;81:1966.
[4] Barletta V, Herranz E, Treaba CA, et al. Quantitative 7-Tesla Imaging of Cortical Myelin Changes in Early Multiple Sclerosis. Frontiers in Neurology 2021;12.
[5] Ge Y, Zohrabian VM, Osa EO, et al. Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. J Magn Reson Imaging 2009;29:1190-4.
Ge, Y. (2022). Seeing is believing: ultra-high field magnetic resonance imaging in vascular and neurodegeneration research. Veins and Lymphatics, 11(1). https://doi.org/10.4081/vl.2022.10941

Downloads

Download data is not yet available.

Citations